MAP2K7 and neoplasm: Preclinical models combining MEK inhibitors with ICI showed additional activity over the individual drugs alone, and in mouse models, treatment with cobimetinib alone impeded tumor growth, and in combination with anti-PD-L1 therapy, tumor growth was further inhibited and some complete responses were observed [175,176,177].